FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis Presented ByDr Javier Sastre, Hospital Clínico San Carlos, Spain TrialPhase 3, VISNU-1 ConferenceASCO 2019 15 July, 2019 23:53